---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007566"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:45:17.171032+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Bio Q1 WAKIX revenue $119.1M (+40% YoY); GAAP EPS $0.48; patients ~5,200

## Summary
- Net product revenue $119.1M, +39.6% YoY; GAAP net income $29.5M ($0.48 diluted EPS) vs $21.5M ($0.35) prior year.
- Average patients on WAKIX ~5,100 (+1,200 YoY); exited Q1 with ~5,200 patients.
- Cumulative WAKIX net revenue surpassed $1B since launch; Phase 3 IH INTUNE topline data expected Q4 2023.
- Non-GAAP adjusted net income $40.1M ($0.66 diluted EPS) vs $31.1M ($0.51) prior year.

## SEC filing metadata
- accession: 0001558370-23-007566
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/0001558370-23-007566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/hrmy-20230502x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007566
- JSON: https://secwatch.observer/filing/0001558370-23-007566.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007566.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported quarter ended March 31, 2023 results: revenue $119.1 million, net income $29.5 million, EPS $0.48.
  - Period: quarter ended March 31, 2023
  - Revenue: $119.1 million
  - Net income: $29.5 million
  - EPS: $0.48
  - Result: reported results
  source text: --- ‌ Exhibit 99.1 ​ HARMONY BIOSCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 ​ Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter 2023 ​ Exited First Quarter 2023 With ~5,200 Patients on
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/0001558370-23-007566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.